GoldBamboo.com - Knowledge is strong medicine
  

MAP Pharmaceuticals Reports Positive Phase 2 Results For Its Pediatric Asthma Drug Candidate - News


  Not Signed In - Sign In / Register




General Topics A-Z

MAP Pharmaceuticals Reports Positive Phase 2 Results For Its Pediatric Asthma Drug Candidate

Wed, 28 Feb 2007 08:00 AM EST

... MAP Pharmaceuticals, Inc. announced today that its Unit Dose Budesonide (UDB) drug candidate met its primary efficacy endpoints in a Phase 2 clinical trial. UDB is a proprietary nebulized formulation of budesonide for treatment of pediatric asthma. The multicenter, randomized, double-blind, placebo-controlled U.S. [click link for full article] ...

Related Topics

Take control over your directory listings...INSTANTLY

Every day, thousands of users find businesses like yours in the GoldBamboo directory.

Limited Time Offer!!!

For only $50 a year, a savings of 50% off our standard rate:

  • Edit your listing (whenever you want!)
  • Link to your website
  • Choose which categories you are listed in
  • Describe your services

The process will take only a few minutes and consists of 3 easy steps:

1. Register     >     2. Edit Listings     >     3. Publish

Your Company
your street
yourtown, YS 12345
888-888-8888



No Thanks

GoldBambooTM

Your Integrative Health and Wellness Resource

July 23, 2008


Page Updated: June 12, 2007
Disclaimer: All material displayed on the GoldBamboo.com website is provided for educational purposes only. Consult a physician regarding the applicability of any information found on GoldBamboo.com to your symptoms or medical condition.

Insurance Quotes | Home | About Us | Link To Us | Feedback | Disclaimer | Privacy Policy | Terms of Use | Google Co-op | Health Forums

Copyright © 2004-2008 - Gold Bamboo LLC
All rights reserved.

HONcode accreditation seal.

We comply with the HONcode standard for health trust worthy information:
verify here.